Syncom Formulations (India) peers

Companies like Syncom Formulations (India)latest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,911 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SYNCOMF
FY26
HESTERBIO
FY26
NGLFINE
FY26
WINDLAS
FY26
Peer
Average
Valuation — at last close
P/E◆ 25.10×33.21×33.51×28.12×31.61× -21%
P/B4.61×5.30×4.90×◆ 3.23×4.48× +3%
EV/EBITDA23.24×24.21×23.07×◆ 15.61×20.96× +11%
Market Cap₹1,911 Cr₹1,909 Cr₹1,613 Cr₹1,876 Cr₹1,799 Cr +6%
Growth
Revenue CAGR 3Y◆ 29.69%7.72%21.68%20.78%16.73% +78%
Revenue CAGR 5Y—9.19%——9.19%
Net Income CAGR 3Y◆ 56.16%27.04%32.91%15.95%25.30% +122%
Revenue YoY (latest Q)7.38%-8.16%◆ 33.57%17.66%14.36% -49%
Net Income YoY (latest Q)57.71%◆ 459.27%99.09%-1.79%185.52% -69%
Profitability
EBITDA Margin15.83%◆ 26.05%14.51%11.59%17.38% -9%
Net Income Margin15.63%◆ 17.28%9.61%7.35%11.41% +37%
Return on Common Equity◆ 20.19%16.50%15.74%12.23%14.82% +36%
Return on Capital Employed◆ 18.08%12.87%14.96%13.49%13.77% +31%
Return on Assets◆ 16.14%8.64%9.83%7.97%8.81% +83%
Credit & Quality
Total Debt/Equity◆ 0.00×0.51×0.33×0.05×0.30× -100%
Interest Coverage◆ 61.38×6.20×11.89×15.33×11.14× +451%
Scale — latest FY
Revenue / Total Income₹489 Cr₹333 Cr₹501 Cr₹904 Cr₹579 Cr -16%
Net Income₹76.4 Cr₹57.5 Cr₹48.1 Cr₹66.5 Cr₹57.4 Cr +33%
Total Assets₹534 Cr₹678 Cr₹545 Cr₹907 Cr₹710 Cr -25%
EPS₹0.81₹67.57₹77.9₹31.6₹59.02 -99%
Book Value per Share₹4.41₹423.46₹532.91₹275.2₹410.52 -99%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.